Crizotinib (C) in patients (pts) with solid tumors with MET amplification (amp) or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyKathryn F. Mileham,Michael Rothe,Pam K. Mangat,Elizabeth Garrett-Mayer, Herbert L. Duvivier,Carmen J. Calfa,Carrie L. Dul,Alissa S. Marr,Eugene R. Ahn,Deepti Behl,Michael J. Hall,Inderjit Mehmi,Anu Gaba,Rom Leidner,Mark M. Zalupski,Gina N. Grantham,Abigail Gregory,Susan Halabi,Richard L. SchilskyCANCER RESEARCH(2023)引用 0|浏览7暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要